Theravance Biopharma
TBPH
92 hedge funds and large institutions have $1.65B invested in Theravance Biopharma in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 11 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
18% more capital invested
Capital invested by funds: $1.4B → $1.65B (+$256M)
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
1.01% more ownership
Funds ownership: 84.36% → 85.37% (+1%)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
6% less funds holding
Funds holding: 98 → 92 (-6)
69% less call options, than puts
Call options by funds: $732K | Put options by funds: $2.38M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$112M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.8M |
| 3 |
Goldman Sachs
New York
|
+$6.33M |
| 4 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$6.31M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$13M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$12.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.56M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$2.03M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.92M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Creative Planning
Overland Park,
Kansas
| – | -$27K | -835 | Closed |
|
|
IR
102
Invictus RG
Hamilton,
Bermuda
| – | -$1K | -32 | Closed |
|
TBPH Hedge Fund Activity: Q1 2017 in Review
92 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2017, worth a combined $1.65B — up 18% from $1.4B a quarter earlier.
Fund positioning in TBPH was balanced in Q1 2017: 11 funds opened new positions, 11 closed out, 32 added to existing stakes and 29 trimmed.
The largest buyer was BlackRock, adding an estimated $112M. The largest seller was Marshall Wace, exiting entirely with an estimated $13M sold.
- 92 institutional investors held Theravance Biopharma (TBPH) as of Q1 2017, down from 98 in Q4 2016.
- Funds reported $1.65B of Theravance Biopharma stock for Q1 2017, up 18% quarter-over-quarter.
- 11 funds opened new Theravance Biopharma positions in Q1 2017 and 11 closed out, a net change of 0 holders.
- The largest Theravance Biopharma buyer in Q1 2017 was BlackRock, an estimated $112M added.
- The largest Theravance Biopharma seller in Q1 2017 was Marshall Wace, an estimated $13M sold.
Based on aggregated 13F filings for Q1 2017.